WO2012140490A3 - Procédé de préparation de dérivé de quinoléine - Google Patents

Procédé de préparation de dérivé de quinoléine Download PDF

Info

Publication number
WO2012140490A3
WO2012140490A3 PCT/IB2012/000721 IB2012000721W WO2012140490A3 WO 2012140490 A3 WO2012140490 A3 WO 2012140490A3 IB 2012000721 W IB2012000721 W IB 2012000721W WO 2012140490 A3 WO2012140490 A3 WO 2012140490A3
Authority
WO
WIPO (PCT)
Prior art keywords
processes
pitavastatin calcium
preparing pitavastatin
preparing
calcium
Prior art date
Application number
PCT/IB2012/000721
Other languages
English (en)
Other versions
WO2012140490A2 (fr
Inventor
Sukumar Nandi
Balanarasimha Reddy Gona
Naresh Akkina
Narayan Krishna Anjaneya Subramanya Sambho GORIMELLA
Joseph Prabahar Koilpillai
Sivakumaran Meenakshisunderam
Original Assignee
Aurobindo Pharma Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aurobindo Pharma Limited filed Critical Aurobindo Pharma Limited
Publication of WO2012140490A2 publication Critical patent/WO2012140490A2/fr
Publication of WO2012140490A3 publication Critical patent/WO2012140490A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms

Abstract

La présente invention concerne un nouveau procédé de préparation de sel calcique de pitavastatine de formule (I).
PCT/IB2012/000721 2011-04-11 2012-04-10 Procédé de préparation de dérivé de quinoléine WO2012140490A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN1251CH2011 2011-04-11
IN1251/CHE/2011 2011-04-11
IN2458/CHE/2011 2011-07-19
IN2458CH2011 2011-07-19

Publications (2)

Publication Number Publication Date
WO2012140490A2 WO2012140490A2 (fr) 2012-10-18
WO2012140490A3 true WO2012140490A3 (fr) 2013-03-07

Family

ID=46147515

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2012/000721 WO2012140490A2 (fr) 2011-04-11 2012-04-10 Procédé de préparation de dérivé de quinoléine

Country Status (1)

Country Link
WO (1) WO2012140490A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102898367B (zh) * 2012-11-15 2014-04-30 江苏阿尔法药业有限公司 一种匹伐他汀钙原料药中间体的制备方法
CN103848784B (zh) * 2012-12-05 2016-12-21 安徽省庆云医药化工有限公司 匹伐他汀酯的晶型及其制备方法
CN103145613B (zh) * 2013-03-11 2015-04-08 黄河三角洲京博化工研究院有限公司 一种(e)-3-(2-环丙基-4-(4-氟苯基))喹啉-2-丙烯醛的合成方法
CN104016916A (zh) * 2014-05-16 2014-09-03 南通常佑药业科技有限公司 一种匹伐他汀钙中间体的制备方法
WO2017022846A1 (fr) * 2015-08-05 2017-02-09 株式会社エーピーアイ コーポレーション Procédé de production de pitavastatine calcique
CN106749001A (zh) * 2016-11-21 2017-05-31 黄河三角洲京博化工研究院有限公司 一种(e)‑3‑[2‑环丙基‑4‑(4‑氟苯基)‑3‑喹啉‑2‑丙烯醛的合成方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010089770A2 (fr) * 2009-01-19 2010-08-12 Msn Laboratories Limited Procédé amélioré d'élaboration d'acide (3r,5s)-7-[2-cyclopropyl-4-(4-fluorophényl)quinolin-3-yl]-3,5-dihydroxy-6(e)-heptènoïque de haute pureté, y compris ses sels pharmaceutiquement acceptables

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2569746B2 (ja) 1987-08-20 1997-01-08 日産化学工業株式会社 キノリン系メバロノラクトン類
US4761419A (en) 1987-12-07 1988-08-02 Warner-Lambert Company 6-(((substituted)quinolinyl)ethyl)-and ethenyl)tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
US5753675A (en) 1989-03-03 1998-05-19 Novartis Pharmaceuticals Corporation Quinoline analogs of mevalonolactone and derivatives thereof
JP3528186B2 (ja) 1991-06-24 2004-05-17 日産化学工業株式会社 光学活性キノリンメバロン酸のジアステレオマー塩
WO1995011898A1 (fr) 1992-05-12 1995-05-04 Nissan Chemical Industries Ltd. Intermediaire condense de synthese du mevalonolactone de type pyridine et procede de fabrication de cet intermediaire
ES2214169T1 (es) 2001-06-06 2004-09-16 Bristol-Myers Squibb Company Procedimiento de preparacion de sulfonas quirales dioles e inhibidores del dihidroxiacido hmg coa reductasa.
US6835838B2 (en) 2002-01-28 2004-12-28 Novartis Ag Process for the manufacture of organic compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010089770A2 (fr) * 2009-01-19 2010-08-12 Msn Laboratories Limited Procédé amélioré d'élaboration d'acide (3r,5s)-7-[2-cyclopropyl-4-(4-fluorophényl)quinolin-3-yl]-3,5-dihydroxy-6(e)-heptènoïque de haute pureté, y compris ses sels pharmaceutiquement acceptables

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FUJINO, HIDEKI; KOJIMA, JUNJI; YAMADA, YOUICHI; KANDA, HIROYASU; KIMATA, HIDEKI: "studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (4) Interspecies variation in laboratory animals and humans", YAKUBUTSU DOTAI (DRUG METABOLISM AND PHARMACOKINETICS), vol. 14, no. 2, 1999, pages 79 - 91, XP002678275, ISSN: 0916-1139, DOI: 10.2133/dmpk.14.79 *
SUZUKI M ET AL: "First systematic chiral syntheses of two pairs of enantiomers with 3,5-dihydroxyheptenoic acid chain, associated with a potent synthetic statin NK-104", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 9, no. 20, 18 October 1999 (1999-10-18), pages 2977 - 2982, XP025669499, ISSN: 0960-894X, [retrieved on 19991018], DOI: 10.1016/S0960-894X(99)00519-3 *

Also Published As

Publication number Publication date
WO2012140490A2 (fr) 2012-10-18

Similar Documents

Publication Publication Date Title
MX361653B (es) Procedimiento para la preparación de derivados del ácido biliar.
WO2011138281A3 (fr) Procédé de production de dithiine-tétracarboxy-diimides
EP2674395A4 (fr) Procédé pour la production de sel d'ammonium de fluorosulfonylimide
SI2697218T1 (sl) Postopek za pripravo spojin, koristnih kot zaviralci sglt2
EP2563791A4 (fr) Procédé de préparation d'un sel d'ammonium quaternaire à l'aide d'un phosphate
WO2013014665A8 (fr) Composés intermédiaires et procédé pour la préparation de lurasidone et de sels de celle-ci
WO2011157390A3 (fr) Procédé de préparation de composés 3-(1-amino-2-methylpentane-3-yl)phényle substitué
MY160902A (en) Process for the preparation of the L-arginine salt of perindopril
WO2012140490A3 (fr) Procédé de préparation de dérivé de quinoléine
IN2014CN04449A (fr)
WO2013111162A3 (fr) Procédé pour la préparation de fingolimod
WO2014087208A3 (fr) Procédé de préparation d'alcaftadine
EP2688888A4 (fr) Procédé pour la production d'un sel de pémétrexed
MX350430B (es) Proceso para preparar compuestos acido 4-amino-5-bifenil-4-il-2-hi droximetil-2-metil-pentanoico.
ZA201304938B (en) Process for producing nitrile-fatty acid compounds
IN2014MN00971A (fr)
MX2012010443A (es) Proceso para la preparacion de 1-alquiltetrazoles 5-sustituidos.
MY191759A (en) Processes for the preparation of pyrimidinylcyclopentane compounds
WO2013190357A8 (fr) Procédé pour la fabrication de gabapentine
WO2014068333A3 (fr) Nouveau procédé
IN2014DN09451A (fr)
WO2013072938A3 (fr) Procédé amélioré pour la préparation de roflumilast
IN2012DN02000A (fr)
EP2776388A4 (fr) Procédé inédit de préparation de (r)-n-benzyl-2-acétamido-3-méthoxypropionamide
WO2014041558A3 (fr) Procédé de préparation d'étoricoxib cristallin

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12722831

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12722831

Country of ref document: EP

Kind code of ref document: A2